Which has preferable earnings & valuation, QGEN or ILMN?

Illumina has higher revenue and earnings than Qiagen. Qiagen is trading at a lower price-to-earnings ratio than Illumina, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Qiagen $2.09B 4.28 $424.88M $1.95 22.24 Illumina $4.34B 8.33 $850M $5.36 44.71

Is QGEN or ILMN more profitable?

Qiagen has a net margin of 19.49% compared to Illumina's net margin of 18.36%. Illumina's return on equity of 29.84% beat Qiagen's return on equity. Company Net Margins Return on Equity Return on Assets Qiagen 19.49% 14.47% 8.34% Illumina 18.36% 29.84% 12.17%

Does the media favor QGEN or ILMN?

In the previous week, Qiagen had 1 more articles in the media than Illumina. MarketBeat recorded 14 mentions for Qiagen and 13 mentions for Illumina. Illumina's average media sentiment score of 0.86 beat Qiagen's score of 0.58 indicating that Illumina is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Qiagen 4 Very Positive mention(s) 3 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Illumina 8 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor MTD or QGEN?

In the previous week, Qiagen had 6 more articles in the media than Mettler-Toledo International. MarketBeat recorded 14 mentions for Qiagen and 8 mentions for Mettler-Toledo International. Mettler-Toledo International's average media sentiment score of 1.01 beat Qiagen's score of 0.58 indicating that Mettler-Toledo International is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mettler-Toledo International 4 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Qiagen 4 Very Positive mention(s) 3 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation & earnings, MEDP or QGEN?

Medpace has higher revenue and earnings than Qiagen. Qiagen is trading at a lower price-to-earnings ratio than Medpace, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Medpace $2.53B 6.75 $451.12M $17.06 35.89 Qiagen $2.09B 4.28 $424.88M $1.95 22.24

Is MEDP or QGEN more profitable?

Qiagen has a net margin of 19.49% compared to Medpace's net margin of 17.67%. Medpace's return on equity of 110.15% beat Qiagen's return on equity. Company Net Margins Return on Equity Return on Assets Medpace 17.67% 110.15% 24.84% Qiagen 19.49% 14.47% 8.34%

Does the media refer more to MEDP or QGEN?

In the previous week, Qiagen had 3 more articles in the media than Medpace. MarketBeat recorded 14 mentions for Qiagen and 11 mentions for Medpace. Medpace's average media sentiment score of 0.86 beat Qiagen's score of 0.58 indicating that Medpace is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Medpace 8 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Qiagen 4 Very Positive mention(s) 3 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation and earnings, QGEN or RVTY?

Qiagen has higher earnings, but lower revenue than Revvity. Qiagen is trading at a lower price-to-earnings ratio than Revvity, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Qiagen $2.09B 4.28 $424.88M $1.95 22.24 Revvity $2.86B 5.61 $241.20M $2.10 68.38

Is QGEN or RVTY more profitable?

Qiagen has a net margin of 19.49% compared to Revvity's net margin of 8.16%. Qiagen's return on equity of 14.47% beat Revvity's return on equity. Company Net Margins Return on Equity Return on Assets Qiagen 19.49% 14.47% 8.34% Revvity 8.16% 8.34% 5.01%

Does the media refer more to QGEN or RVTY?

In the previous week, Qiagen had 2 more articles in the media than Revvity. MarketBeat recorded 14 mentions for Qiagen and 12 mentions for Revvity. Revvity's average media sentiment score of 0.63 beat Qiagen's score of 0.58 indicating that Revvity is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Qiagen 4 Very Positive mention(s) 3 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Revvity 5 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Qiagen (QGEN) Competitors

$43.37 -1.01 (-2.27%)

Closing price 03:59 PM Eastern

Extended Trading

$43.34 -0.03 (-0.07%)

As of 07:30 PM Eastern

Compare

QGEN vs. ILMN, MTD, MEDP, RVTY, and CRL

Should you buy Qiagen stock or one of its competitors? Qiagen's main competitors and comparable companies include Illumina (ILMN), Mettler-Toledo International (MTD), Medpace (MEDP), Revvity (RVTY), and Charles River Laboratories International (CRL). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "life sciences tools & services" industry.

How does Qiagen compare to Illumina?

Qiagen (NYSE:QGEN) and Illumina (NASDAQ:ILMN) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, risk, valuation, analyst recommendations, dividends, earnings and profitability.

In the previous week, Qiagen had 1 more articles in the media than Illumina. MarketBeat recorded 14 mentions for Qiagen and 13 mentions for Illumina. Illumina's average media sentiment score of 0.86 beat Qiagen's score of 0.58 indicating that Illumina is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Qiagen	4 Very Positive mention(s)	3 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Illumina	8 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Qiagen has a beta of 0.63, indicating that its share price is 37% less volatile than the broader market. Comparatively, Illumina has a beta of 1.46, indicating that its share price is 46% more volatile than the broader market.

Illumina has higher revenue and earnings than Qiagen. Qiagen is trading at a lower price-to-earnings ratio than Illumina, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Qiagen	$2.09B	4.28	$424.88M	$1.95	22.24
Illumina	$4.34B	8.33	$850M	$5.36	44.71

70.0% of Qiagen shares are held by institutional investors. Comparatively, 89.4% of Illumina shares are held by institutional investors. 9.0% of Qiagen shares are held by company insiders. Comparatively, 2.9% of Illumina shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Qiagen has a net margin of 19.49% compared to Illumina's net margin of 18.36%. Illumina's return on equity of 29.84% beat Qiagen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Qiagen	19.49%	14.47%	8.34%
Illumina	18.36%	29.84%	12.17%

Qiagen currently has a consensus price target of $43.51, indicating a potential upside of 0.31%. Illumina has a consensus price target of $199.13, indicating a potential downside of 16.90%. Given Qiagen's higher probable upside, equities research analysts clearly believe Qiagen is more favorable than Illumina.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Qiagen	0 Sell rating(s)	9 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.43
Illumina	2 Sell rating(s)	6 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.44

Summary

Illumina beats Qiagen on 12 of the 17 factors compared between the two stocks.

How does Qiagen compare to Mettler-Toledo International?

Mettler-Toledo International (NYSE:MTD) and Qiagen (NYSE:QGEN) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, dividends, analyst recommendations, profitability, risk, valuation and earnings.

In the previous week, Qiagen had 6 more articles in the media than Mettler-Toledo International. MarketBeat recorded 14 mentions for Qiagen and 8 mentions for Mettler-Toledo International. Mettler-Toledo International's average media sentiment score of 1.01 beat Qiagen's score of 0.58 indicating that Mettler-Toledo International is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mettler-Toledo International	4 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Qiagen	4 Very Positive mention(s)	3 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Mettler-Toledo International currently has a consensus price target of $1,446.36, indicating a potential upside of 3.82%. Qiagen has a consensus price target of $43.51, indicating a potential upside of 0.31%. Given Mettler-Toledo International's higher probable upside, equities research analysts plainly believe Mettler-Toledo International is more favorable than Qiagen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mettler-Toledo International	1 Sell rating(s)	9 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.31
Qiagen	0 Sell rating(s)	9 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.43

Mettler-Toledo International has a beta of 1.22, meaning that its stock price is 22% more volatile than the broader market. Comparatively, Qiagen has a beta of 0.63, meaning that its stock price is 37% less volatile than the broader market.

95.1% of Mettler-Toledo International shares are owned by institutional investors. Comparatively, 70.0% of Qiagen shares are owned by institutional investors. 0.7% of Mettler-Toledo International shares are owned by insiders. Comparatively, 9.0% of Qiagen shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Mettler-Toledo International has a net margin of 21.91% compared to Qiagen's net margin of 19.49%. Qiagen's return on equity of 14.47% beat Mettler-Toledo International's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mettler-Toledo International	21.91%	-1,212.14%	25.11%
Qiagen	19.49%	14.47%	8.34%

Mettler-Toledo International has higher revenue and earnings than Qiagen. Qiagen is trading at a lower price-to-earnings ratio than Mettler-Toledo International, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mettler-Toledo International	$4.03B	6.93	$869.19M	$44.43	31.36
Qiagen	$2.09B	4.28	$424.88M	$1.95	22.24

Summary

Mettler-Toledo International beats Qiagen on 12 of the 17 factors compared between the two stocks.

How does Qiagen compare to Medpace?

Medpace (NASDAQ:MEDP) and Qiagen (NYSE:QGEN) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, dividends, risk, earnings, analyst recommendations, media sentiment, valuation and profitability.

Medpace has a beta of 1.15, meaning that its stock price is 15% more volatile than the broader market. Comparatively, Qiagen has a beta of 0.63, meaning that its stock price is 37% less volatile than the broader market.

In the previous week, Qiagen had 3 more articles in the media than Medpace. MarketBeat recorded 14 mentions for Qiagen and 11 mentions for Medpace. Medpace's average media sentiment score of 0.86 beat Qiagen's score of 0.58 indicating that Medpace is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Medpace	8 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Qiagen	4 Very Positive mention(s)	3 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Medpace presently has a consensus price target of $595.20, indicating a potential downside of 2.80%. Qiagen has a consensus price target of $43.51, indicating a potential upside of 0.31%. Given Qiagen's stronger consensus rating and higher possible upside, analysts clearly believe Qiagen is more favorable than Medpace.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Medpace	0 Sell rating(s)	9 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.25
Qiagen	0 Sell rating(s)	9 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.43

Medpace has higher revenue and earnings than Qiagen. Qiagen is trading at a lower price-to-earnings ratio than Medpace, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Medpace	$2.53B	6.75	$451.12M	$17.06	35.89
Qiagen	$2.09B	4.28	$424.88M	$1.95	22.24

Qiagen has a net margin of 19.49% compared to Medpace's net margin of 17.67%. Medpace's return on equity of 110.15% beat Qiagen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Medpace	17.67%	110.15%	24.84%
Qiagen	19.49%	14.47%	8.34%

78.0% of Medpace shares are held by institutional investors. Comparatively, 70.0% of Qiagen shares are held by institutional investors. 20.5% of Medpace shares are held by company insiders. Comparatively, 9.0% of Qiagen shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Medpace beats Qiagen on 11 of the 17 factors compared between the two stocks.

How does Qiagen compare to Revvity?

Qiagen (NYSE:QGEN) and Revvity (NYSE:RVTY) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, media sentiment, earnings, profitability, valuation, dividends and risk.

Qiagen pays an annual dividend of $0.35 per share and has a dividend yield of 0.8%. Revvity pays an annual dividend of $0.28 per share and has a dividend yield of 0.2%. Qiagen pays out 17.9% of its earnings in the form of a dividend. Revvity pays out 13.3% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

In the previous week, Qiagen had 2 more articles in the media than Revvity. MarketBeat recorded 14 mentions for Qiagen and 12 mentions for Revvity. Revvity's average media sentiment score of 0.63 beat Qiagen's score of 0.58 indicating that Revvity is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Qiagen	4 Very Positive mention(s)	3 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Revvity	5 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Qiagen has a net margin of 19.49% compared to Revvity's net margin of 8.16%. Qiagen's return on equity of 14.47% beat Revvity's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Qiagen	19.49%	14.47%	8.34%
Revvity	8.16%	8.34%	5.01%

Qiagen has higher earnings, but lower revenue than Revvity. Qiagen is trading at a lower price-to-earnings ratio than Revvity, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Qiagen	$2.09B	4.28	$424.88M	$1.95	22.24
Revvity	$2.86B	5.61	$241.20M	$2.10	68.38

70.0% of Qiagen shares are held by institutional investors. Comparatively, 86.7% of Revvity shares are held by institutional investors. 9.0% of Qiagen shares are held by company insiders. Comparatively, 0.9% of Revvity shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Qiagen presently has a consensus target price of $43.51, indicating a potential upside of 0.31%. Revvity has a consensus target price of $116.57, indicating a potential downside of 18.82%. Given Qiagen's stronger consensus rating and higher possible upside, equities analysts clearly believe Qiagen is more favorable than Revvity.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Qiagen	0 Sell rating(s)	9 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.43
Revvity	0 Sell rating(s)	14 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.22

Qiagen has a beta of 0.63, suggesting that its share price is 37% less volatile than the broader market. Comparatively, Revvity has a beta of 1.09, suggesting that its share price is 9% more volatile than the broader market.

Summary

Qiagen beats Revvity on 10 of the 18 factors compared between the two stocks.

How does Qiagen compare to Charles River Laboratories International?

Charles River Laboratories International (NYSE:CRL) and Qiagen (NYSE:QGEN) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, dividends, analyst recommendations, media sentiment, earnings and profitability.

Qiagen has lower revenue, but higher earnings than Charles River Laboratories International. Charles River Laboratories International is trading at a lower price-to-earnings ratio than Qiagen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Charles River Laboratories International	$4.02B	3.30	-$144.34M	-$4.85	N/A
Qiagen	$2.09B	4.28	$424.88M	$1.95	22.24

In the previous week, Qiagen had 8 more articles in the media than Charles River Laboratories International. MarketBeat recorded 14 mentions for Qiagen and 6 mentions for Charles River Laboratories International. Charles River Laboratories International's average media sentiment score of 0.95 beat Qiagen's score of 0.58 indicating that Charles River Laboratories International is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Charles River Laboratories International	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Qiagen	4 Very Positive mention(s)	3 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Charles River Laboratories International presently has a consensus price target of $273.81, indicating a potential downside of 1.40%. Qiagen has a consensus price target of $43.51, indicating a potential upside of 0.31%. Given Qiagen's higher probable upside, analysts clearly believe Qiagen is more favorable than Charles River Laboratories International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Charles River Laboratories International	1 Sell rating(s)	3 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.67
Qiagen	0 Sell rating(s)	9 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.43

Qiagen has a net margin of 19.49% compared to Charles River Laboratories International's net margin of -5.96%. Charles River Laboratories International's return on equity of 15.75% beat Qiagen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Charles River Laboratories International	-5.96%	15.75%	6.51%
Qiagen	19.49%	14.47%	8.34%

98.9% of Charles River Laboratories International shares are held by institutional investors. Comparatively, 70.0% of Qiagen shares are held by institutional investors. 1.3% of Charles River Laboratories International shares are held by company insiders. Comparatively, 9.0% of Qiagen shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Charles River Laboratories International has a beta of 1.4, meaning that its share price is 40% more volatile than the broader market. Comparatively, Qiagen has a beta of 0.63, meaning that its share price is 37% less volatile than the broader market.

Summary

Qiagen beats Charles River Laboratories International on 10 of the 17 factors compared between the two stocks.

Get Qiagen News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding QGEN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

QGEN vs. The Competition

Export

Metric	Qiagen	Life Sciences Tools & Services Industry	Healthcare Sector	NYSE Exchange
Market Cap	$9.15B	$10.48B	$7.26B	$23.14B
Dividend Yield	0.79%	1.46%	2.57%	3.59%
P/E Ratio	22.23	56.65	213.39	24.39
Price / Sales	4.28	108.54	644.45	20.33
Price / Cash	13.03	27.34	77.42	34.53
Price / Book	2.42	5.70	10.45	4.67
Net Income	$424.88M	$56.67B	$3.48B	$1.07B
7 Day Performance	2.32%	4.28%	0.88%	-1.65%
1 Month Performance	2.35%	4.87%	0.03%	-3.58%
1 Year Performance	-9.93%	27.19%	18.28%	7.58%

Qiagen Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
QGEN Qiagen	3.6178 of 5 stars	$43.37 -2.3%	$43.51 +0.3%	-7.2%	$9.15B	$2.09B	22.23	5,654	News Coverage
ILMN Illumina	1.9753 of 5 stars	$208.21 +0.9%	$199.13 -4.4%	+143.1%	$31.17B	$4.34B	38.85	8,650
MTD Mettler-Toledo International	4.0131 of 5 stars	$1,285.72 -0.6%	$1,446.36 +12.5%	+10.7%	$25.92B	$4.03B	28.94	18,100	Positive News
MEDP Medpace	2.3921 of 5 stars	$595.41 +1.3%	$595.20 0.0%	+23.6%	$16.40B	$2.53B	34.90	6,200	Insider Trade
RVTY Revvity	2.5598 of 5 stars	$128.57 +3.4%	$116.57 -9.3%	+71.9%	$13.87B	$2.86B	61.22	11,000	Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:QGEN) was last updated on 9/18/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Qiagen (QGEN) Competitors